

BB BIOTECH AG CHF0.20 (REGD)

ISIN: CH0038389992 WKN: 3838999 Asset Class: **Stock**

Company

2024/10/18 17:30:09

Price

37.35 CHF

Difference ▲ 0.67%(0.25)

Contact Details

BB BIOTECH AG Tel: +41-52-624-08-45
 -- Fax: +
 Schwertstrasse 6 Web: <http://www.bbbiotech.com>
 8200 Schaffhausen E-mail: info@bbbiotech.com



Company Profile

BB Biotech AG provides investment services for biotechnology sector. It invests in portfolio of companies that are engaged in developing and marketing of innovative biotech drugs. It offers investors a exposure to a focused portfolio of predominantly-US small-to-mid-cap biotech companies developing therapeutic products, towards cell, gene and particularly RNA-based technologies. The company was founded on November 9, 1993 and is headquartered in Schaffhausen, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	-	-	-	-	-	-
Common stock capital		11,080,000		11,080,000		11,080,000
Fixed assets	-	-	-	-	-	-
Equity capital of a company		2,323,217,000		2,686,135,000		3,283,493,000
Cash and cash equivalents	501,000		1,948,000		2,835,000	
Accrued liabilities		0		0		0
Other assets	-	-	-	-	-	-
Current liabilities		-		-		-
Prepayments and accrued income	-	-	-	-	-	-
Non-current liabilities		-		-		-
Different income		-		-		-
Other liabilities		9,037,000		4,254,000		5,589,000
Total assets	2,637,154,000	2,637,154,000	3,053,389,000	3,053,389,000	3,644,082,000	3,644,082,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	-	-	-
Equity ratio	88.10%	87.97%	90.10%
Debt-equity ratio	13.51%	13.67%	10.98%

Others

	2023	2022	2021
Tax Expense Rate	-0.04%	-0.02%	-0.02%

BB BIOTECH AG CHF0.20 (REGD)

ISIN: CH0038389992 WKN: 3838999 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	-17,264,000	-28,350,000	307,660,000
Net income	-206,607,000	-357,812,000	-404,808,000
EBIT	-219,329,100	-380,138,020	-429,999,618
Operating income before taxes	-206,528,000	-357,751,000	-404,741,000
Cash Flow	212,474,000	229,405,000	-95,773,000
Net interest income	-411,000	-512,000	-644,000
Research and development expenses	-	-	-
Income taxes	79,000	61,000	67,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	-	-	-

Board of Directors

Clive Meanwell	Member of the administrative board
Mads Krogsgaard Thomsen	Member of the administrative board
Pearl Shirley Huang	Member of the administrative board
Camilla Soenderby	Member of the administrative board
Laura Hamill	Member of the administrative board
Thomas von Planta	Chairman of the administrative board

Members of Management Board

Daniel Koller	Member of Executive Committee
Felicia Flanigan	Member of Executive Committee